臨床外科74巻11号

2019年10月発行

増刊号 すぐに使える周術期管理マニュアル

Ⅴ章　特殊な治療手技

血液浄化療法・PMX-DHP

著者： 小野聡¹ 青笹季文¹ 蒲池良平¹ 岡崎幸生¹

所属機関： ¹新久喜総合病院消化器センター

ページ範囲：P.344 - P.348

文献概要

血液浄化療法とは
　血液浄化療法は血液中に存在する病因物質を体外循環を通して除去，場合によっては不足しているものを補う治療法で，血液透析（hemodialysis：HD），血液濾過（hemofiltration：HF），血液濾過透析（hemodiafiltration：HDF），血漿交換（plasma exchange），血液吸着（hemoadsorption），血漿吸着（plasma adsorption），血球吸着（cytapheresis）などがあり，最も広く行われている血液浄化療法は，慢性腎不全患者に対して行う血液透析である．
　本稿では外科周術期および集中治療領域で施行されることの多い持続的血液濾過透析（continuous hemodiafiltration：CHDF）と2014年から保険適用となったセプザイリス^®によるサイトカイン吸着除去，そしてエンドトキシン吸着療法（polymyxin B-direct hemoperfusion：PMX-DHP）について述べる．

参考文献

1）Ronco C, et al：Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure：a prospective randomised trial. Lancet 356：26-30, 2000

2）Brochard L, et al：An official ATS/ERS/ESICM/SCCM/SRLF statement：prevention and management of acute renal failure in the ICU patient：an international consensus conference in intensive care medicine. Am J Respir Crit Care Med 181：1128-1155, 2010

3）Joannes-Boyau O, et al：High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury（IVOIRE study）：a multicentre randomized controlled trial. Intensive Care Med 39：1535-1546, 2013

4）Hirayama Y, et al：Comparison of interleukin-6 removal properties among hemofilters consisting of varing membrane materials and surface areas：an invitro study. Blood Purif 31：18-25, 2011

5）Hirasawa H, et al：Continuous hemodiafiltration with a cytokine-adsorbing hemofilter for sepsis. Blood Purif 34：164-170, 2012

6）Aoki H, et al：Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 167：412-417, 1994

7）Ono S, et al：Modulation of HLA-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am J Surg 188：150-156, 2004

8）Tsujimoto H, et al：Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16＋CD14＋ monocytes in patients with septic shock. J Endotoxin Res 10：229-237, 2004

9）Vincent JL, et al：A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23：400-405, 2005

10）Cruz DN, et al：Early use of polymyxin B hemoperfusion in abdominal septic shock：the EUPHAS randomized controlled trial. JAMA 301：2445-2452, 2009

11）Payen DM, et al：Early us of polymyxin B hemoperfusion in patients with septic shock due to peritonitis：a multicenter randomized control trial. Intensive Care Med 41：975-984, 2015

12）Dellinger RP, et al：Effects of targeted polymyxin B hemoperfusion on 28-day mortality in patinets with septic shock and elevated endotoxin level. The EUPHRATES randomized clinical trial. JAMA 320：1455-1463, 2018

13）Iwagami M, et al：Postoperativ polymyxin B hemoperfusion and mortality in patients with abdominal septic shock：a propensity-matched analysis. Crit Care Med 42：1187-1193, 2014

14）Iwagami M, et al：Potential survival benefit of polymyxin B hemoperfusion in septic shock patients on continuous renal replacement therapy：A propensity-matched analysis. Blood Purif 42：9-17, 2016

15）Nakamura Y, et al：Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock：a propensity-matched cohort study. Critical Care 21：134-142, 2017

16）Chang T, et al：Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock：a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med 45：e858-e864, 2017

17）Varga K, et al：Platelet and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12：1035, 1998

18）Wang T, et al：Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FASEB Letters 470：151-155, 2000

19）Ono S, et al：Removal of increased circulating CD4（＋）CD25（＋）Foxp3（＋） regulatory T cells in patients with septic shock using hemoperfusion with polymyxin B-immobilized fibers. Surgery 153：262-271, 2013

20）Ono S, et al：Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis. Ann Gastroenterol Surg 2：351-358, 2018

21）Srisawat N, et al：The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Critical Care 22：279-289, 2018